MUSC Hollings Cancer Center researchers are exploring the use of peptide carriers for the delivery of small RNA drugs as a novel treatment for cancer. The team’s recent work, published online March 19 in the Molecular Therapy—Nucleic Acids journal, lays the foundation for developing a clinically relevant peptide carrier RNAi-based drug treatment strategy for human oral cancer.